Evidence map›Paper›PMID 33724718›Full record

ArticleJournal of the International AIDS Society2021

Estimating HIV transmissions in a large U.S. clinic-based sample: effects of time and syndemic conditions.

Satyanand Satyanarayana, Steven A Safren, Brooke G Rogers, Sierra A Bainter, Katerina A Christopoulos, Rob J Fredericksen, William C Mathews, Richard D Moore, Michael J Mugavero, Sonia Napravnik and 4 more

Abstract read
In one paragraph

Article in Journal of the International AIDS Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Satyanand SatyanarayanaDepartment of Psychology, University of Miami, Coral Gables, FL, USA.ORCID 0000-0002-4389-2905
Steven A SafrenDepartment of Psychology, University of Miami, Coral Gables, FL, USA.ORCID 0000-0002-0121-0806
Brooke G RogersDepartment of Psychology, University of Miami, Coral Gables, FL, USA.ORCID 0000-0002-8569-9556
Sierra A BainterDepartment of Psychology, University of Miami, Coral Gables, FL, USA.
Katerina A ChristopoulosDepartment of Medicine, UCSF School of Medicine, San Francisco, CA, USA.
Rob J FredericksenDepartment of Medicine, University of Washington School of Medicine, Seattle, WA, USA.
William C MathewsUCSD School of Medicine, San Diego, CA, USA.
Richard D MooreJohns Hopkins University School of Medicine, Baltimore, MD, USA.
Michael J MugaveroUAB School of Medicine, Birmingham, AL, USA.
Sonia NapravnikUNC School of Medicine, Chapel Hill, NC, USA.
Adam W CarricoDepartment of Public Health Sciences, University of Miami School of Medicine, Miami, FL, USA.ORCID 0000-0002-8146-5701
Matthew J MimiagaThe Fenway Institute at Fenway Health, Boston, MA, USA.
Kenneth H MayerThe Fenway Institute at Fenway Health, Boston, MA, USA.ORCID 0000-0001-7460-733X
Heidi M CraneDepartment of Medicine, University of Washington School of Medicine, Seattle, WA, USA.ORCID 0000-0002-3308-7005

Funding

University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI EDWIN ROBERTO ORELLANA · 1988 to 2026
$104.9M
Unsolicited R24 for the CFAR-Network of Integrated Clinical Sciences, CNICSR24AI067039 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Michael S. Saag · 2006 to 2026
$99.4M
The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI RAJESH T GANDHI · 2004 to 2026
$94.4M
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 1988 to 2026
$93.6M
Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Latesha Ellen Elopre · 1988 to 2026
$84.1M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI David Mitchell Smith · 1994 to 2026
$78.4M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
WG3: HIV, Co-infections and Co-morbiditiesP30AI036219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI Alan David Levine · 1994 to 2026
$50.0M
Johns Hopkins HIV Clinical CohortU01DA036935 · NIDA · JOHNS HOPKINS UNIVERSITY · PI MOORE, RICHARD DOUGLAS · 2014 to 2024
$14.9M
University of Miami Developmental HIV/AIDS Mental Health Research Center (D-ARC)P30MH116867 · NIMH · UNIVERSITY OF MIAMI CORAL GABLES · PI SAFREN, STEVEN A · 2019 to 2023
$6.5M
3/4 Alcohol Research Consortium in HIV - Epidemiological Research Arm (ARCH-ERA)U01AA020793 · NIAAA · UNIVERSITY OF WASHINGTON · PI CRANE, HEIDI M., LAU, BRYAN · 2011 to 2020
$5.8M
NIAAA NIH HHS U01 AA020793NIAAA NIH HHS U01 AA020802NIAAA NIH HHS U24 AA020801NIAID NIH HHS P30 AI027757NIAID NIH HHS P30 AI027763NIAID NIH HHS P30 AI027767NIAID NIH HHS P30 AI036214NIAID NIH HHS P30 AI036219NIAID NIH HHS P30 AI050410NIAID NIH HHS P30 AI060354NIAID NIH HHS P30 AI094189NIAID NIH HHS R24 AI067039NIDA NIH HHS K24 DA040489NIDA NIH HHS R01 DA047045NIDA NIH HHS U01 DA036935NIMH NIH HHS K01 MH122805NIMH NIH HHS P30 MH116867
6 · The paper itself

Abstract

introductionLittle is known about onward HIV transmissions from people living with HIV (PLWH) in care. Antiretroviral therapy (ART) has increased in potency, and treatment as prevention (TasP) is an important component of ending the epidemic. Syndemic theory has informed modelling of HIV risk but has yet to inform modelling of HIV transmissions.

methodsData were from 61,198 primary HIV care visits for 14,261 PLWH receiving care through the Centers for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS) at seven United States (U.S.) sites from 2007 to 2017. Patient-reported outcomes and measures (PROs) of syndemic conditions - depressive symptoms, anxiety symptoms, drug use (opiates, amphetamines, crack/cocaine) and alcohol use - were collected approximately four to six months apart along with sexual behaviours (mean = 4.3 observations). Counts of syndemic conditions, HIV sexual risk group and time in care were modelled to predict estimated HIV transmissions resulting from sexual behaviour and viral suppression status (HIV RNA < 400/mL) using hierarchical linear modelling.

resultsPatients averaged 0.38 estimated HIV transmissions/100 patients/year for all visits with syndemic conditions measured (down from 0.83, first visit). The final multivariate model showed that per 100 patients, each care visit predicted 0.05 fewer estimated transmissions annually (95% confidence interval (CI): 0.03 to 0.06; p < 0.0005). Cisgender women, cisgender heterosexual men and cisgender men of undisclosed sexual orientation had, respectively, 0.47 (95% CI: 0.35 to 0.59; p < 0.0005), 0.34 (95% CI: 0.20 to 0.49; p < 0.0005) and 0.22 (95% CI: 0.09 to 0.35; p < 0.005) fewer estimated HIV transmissions/100 patients/year than cisgender men who have sex with men (MSM). Each within-patient syndemic condition predicted 0.18 estimated transmissions/100 patients/year (95% CI: 0.12 to 0.24; p < 0.0005). Each between-syndemic condition predicted 0.23 estimated HIV transmissions/100 patients/year (95% CI: 0.17 to 0.28; p < 0.0005).

conclusionsEstimated HIV transmissions among PLWH receiving care in well-resourced U.S. clinical settings varied by HIV sexual risk group and decreased with time in care, highlighting the importance of TasP efforts. Syndemic conditions remained a significant predictor of estimated HIV transmissions notwithstanding the effects of HIV sexual risk group and time in care.

Indexed as

SyndemicAntiretroviral Therapy, Highly ActiveCohort StudiesContinuity of Patient CareFemaleHIV InfectionsHumansMalePatient Reported Outcome MeasuresSexual BehaviorTime FactorsTreatment OutcomeUnited StatesViral LoadCohort studiesHIV care continuumHIV preventionNorth Americatreatmentviral suppression

Identifiers

PMID33724718
PMCPMC7962793

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.